EGFR and metastatic colorectal cancer: RNF43, a WNT signaling pathway negative regulator, can predict the response of BRAF V600E MSS metastatic colorectal cancer against BRAF/EGFR combination therapy, where MSI-H always carries RNF43 wildtype-like, encoding p.G659fs* and presents an intermediate response frequency (30).